Literature DB >> 27273008

Temporal hollowing and other adverse effects after lateral orbital wall decompression.

Hans Olav Ueland1, Olav H Haugen1,2, Eyvind Rødahl1,2.   

Abstract

PURPOSE: To evaluate the outcome and late postoperative complications after lateral orbital wall decompression in a series of patients with thyroid eye disease (TED).
METHODS: One hundred and three patients operated in the period 1999-2013 were invited to participate in the study, and 84 were included after a median (range) follow-up time of 124 (13-188) months. The patients were interviewed, and preoperative and postoperative data were collected from hospital records. Photographs ('selfies') were obtained from 64 patients. Wilcoxon signed-rank test was used to evaluate the change in pre- and postoperative data.
RESULTS: On average, visual acuity was unchanged with a median value (range) of 1.0 (0.4-1.25) before to 1.0 (0-1.25) after surgery (p = 0.5). Intraocular pressure (IOP) was reduced from a median value (range) of 17 (9-26) to 15 (8-23) mmHg (p < 0.001). Median (range) Hertel values were 23 (15-30) mm preoperatively and 20 (12-26) mm postoperatively (p < 0.001) respectively. Mean (SD) reduction in proptosis was 3.6 (±2.1) mm. Oscillopsia was reported in 24 patients (29%), 42 (50%) experienced a change in temporal sensation, and four (5%) had new-onset diplopia. In 47 patients (56%), some degree of temporal hollowing was reported. Among 64 photographed patients, 38 (59%) had noticeable hollowing on examination of postoperative pictures. There was agreement of the patient's perception of temporal hollowing and the appearance in photographs in 26 of 37 patients (70%).
CONCLUSION: Lateral orbital wall decompression has been considered a safe and effective procedure for treatment of TED. Serious side-effects are infrequent, but in rare circumstances, even blindness may occur. Less serious side-effects are relatively common. Among others, a significant number of the patients developed temporal hollowing after the procedure. The patients must be informed about the possible complications before surgery.
© 2016 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  oscillopsia; proptosis; temporal hollowing; thyroid eye disease; visual acuity

Mesh:

Year:  2016        PMID: 27273008     DOI: 10.1111/aos.13135

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  5 in total

Review 1.  Orbital wall decompression in the management of Graves' orbitopathy: a systematic review with meta-analysis.

Authors:  Federico Maria Gioacchini; Shaniko Kaleci; Ettore Cassandro; Alfonso Scarpa; Michele Tulli; Claudia Cassandro; Massimo Ralli; Massimo Re
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-02-18       Impact factor: 2.503

2.  Management of patients with dysthyroid optic neuropathy treated with intravenous corticosteroids and/or orbital decompression surgery.

Authors:  Sandra Rezar-Dreindl; Andrea Papp; Arnulf Baumann; Thomas Neumayer; Katharina Eibenberger; Eva Stifter; Ursula Schmidt-Erfurth
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-06-22       Impact factor: 3.535

Review 3.  Orbital decompression for thyroid eye disease: methods, outcomes, and complications.

Authors:  J M Jefferis; R K Jones; Z I Currie; J H Tan; S M Salvi
Journal:  Eye (Lond)       Date:  2017-12-15       Impact factor: 3.775

4.  Practice Patterns in Orbital Decompression Surgery Among American Society of Ophthalmic Plastic and Reconstructive Surgery Members.

Authors:  Sarah W DeParis; Jing Tian; Fatemeh Rajaii
Journal:  Ophthalmol Ther       Date:  2019-08-17

5.  Deep Lateral Wall Partial Rim-Sparing Orbital Decompression with Ultrasonic Bone Removal for Treatment of Thyroid-Related Orbitopathy.

Authors:  Álvaro Bengoa-González; Alicia Galindo-Ferreiro; Enrique Mencía-Gutiérrez; Hortensia Sánchez-Tocino; Agustín Martín-Clavijo; María-Dolores Lago-Llinás
Journal:  J Ophthalmol       Date:  2019-12-02       Impact factor: 1.909

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.